These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33377498)

  • 21. Financial disclosure for review authors.
    Nat Neurosci; 2003 Oct; 6(10):997. PubMed ID: 14513027
    [No Abstract]   [Full Text] [Related]  

  • 22. Editorial policies on financial disclosure.
    Carroll BJ; Rubin RT
    Nat Neurosci; 2003 Oct; 6(10):999-1000; author reply 1000-1. PubMed ID: 14513028
    [No Abstract]   [Full Text] [Related]  

  • 23. "Good Publication Practice for Pharmaceutical Companies": where are we now?
    Wager E
    MedGenMed; 2005 Apr; 7(2):6. PubMed ID: 16369385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.
    Alfonso F; Timmis A; Pinto FJ; Ambrosio G; Ector H; Kulakowski P; Vardas P;
    Rev Esp Cardiol (Engl Ed); 2012 May; 65(5):471-8. PubMed ID: 22464101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.
    Li DG; Singer S; Mostaghimi A
    JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unravelling industry bias in clinical trials.
    Gluud LL
    Pain; 2006 Apr; 121(3):175-176. PubMed ID: 16513277
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data.
    Strech D; Littmann J
    Trials; 2012 Jul; 13():100. PubMed ID: 22747684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial policies on financial disclosure.
    Jacobson MF; Sharpe VA; Angell M; Ashford NA; Blum A; Chary LK; Cho M; Coull BC; Davis D; Doolittle RF; Egilman D; Epstein SS; Greenberg M; Hooper K; Huff J; Joshi TK; Krimsky S; LaDou J; Levenstein C; Miles S; Needleman H; Pellegrino ED; Ravanesi B; Sass J; Schecter A; Schneiderman JS; Schubert D; Soffritti M; Suzuki D; Takaro TK; Temple NJ; Terracini B; Thompson A; Wallinga D; Wing S
    Nat Neurosci; 2003 Oct; 6(10):1001. PubMed ID: 14513030
    [No Abstract]   [Full Text] [Related]  

  • 29. Avoiding exploitation in clinical research.
    Benatar SR
    Camb Q Healthc Ethics; 2000; 9(4):562-5. PubMed ID: 11000973
    [No Abstract]   [Full Text] [Related]  

  • 30. Financial conflict of interest: an unresolved ethical frontier.
    Kassirer JP
    Am J Law Med; 2001; 27(2-3):149-62. PubMed ID: 11467107
    [No Abstract]   [Full Text] [Related]  

  • 31. Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia.
    Grundy Q; Habibi R; Shnier A; Mayes C; Lipworth W
    Health Policy; 2018 May; 122(5):509-518. PubMed ID: 29605526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research.
    Tereskerz PM; Moreno J
    Account Res; 2005; 12(2):139-55. PubMed ID: 16220626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should the financial link between industry and physician consultants be severed?
    Immelt SJ; Gaudiani VA; Sade RM
    Ann Thorac Surg; 2011 Sep; 92(3):781-7. PubMed ID: 21871260
    [No Abstract]   [Full Text] [Related]  

  • 34. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach.
    Coleman DL; Kazdin AE; Miller LA; Morrow JS; Udelsman R
    Acad Med; 2006 Feb; 81(2):154-60. PubMed ID: 16436576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment.
    Vera-Badillo FE; Ocana A; Templeton AJ; Tibau A; Amir E; Tannock IF
    J Clin Oncol; 2014 Oct; 32(28):3197. PubMed ID: 25092777
    [No Abstract]   [Full Text] [Related]  

  • 36. New UK guidance on industry-health professional collaboration.
    Mintzes B
    BMJ; 2012 Jun; 344():e3952. PubMed ID: 22700788
    [No Abstract]   [Full Text] [Related]  

  • 37. Towards greater transparency in the life sciences.
    Thompson R; Khanna D
    BMJ; 2012 May; 344():e3371. PubMed ID: 22589510
    [No Abstract]   [Full Text] [Related]  

  • 38. Counterpoint: full disclosure-where is the evidence for nefarious conflicts of interest?
    Sade RM
    Ann Thorac Surg; 2011 Aug; 92(2):417-20. PubMed ID: 21801902
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications.
    Khan R; Scaffidi MA; Rumman A; Grindal AW; Plener IS; Grover SC
    JAMA Intern Med; 2018 Dec; 178(12):1712-1715. PubMed ID: 30383094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Collaboration with drug industry won't affect clinical decisions, says new guide.
    Dyer C
    BMJ; 2012 Apr; 344():e2489. PubMed ID: 22474307
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.